WO2001030288A1 - Oral transmucosal drug dosage using solid solution - Google Patents
Oral transmucosal drug dosage using solid solution Download PDFInfo
- Publication number
- WO2001030288A1 WO2001030288A1 PCT/US2000/028113 US0028113W WO0130288A1 WO 2001030288 A1 WO2001030288 A1 WO 2001030288A1 US 0028113 W US0028113 W US 0028113W WO 0130288 A1 WO0130288 A1 WO 0130288A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formulation
- drug
- pharmaceutical agent
- agent
- dissolution
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
Definitions
- the present invention relates to the improvement of oral transmucosal drug delivery systems.
- the invention relates to solid pharmaceutical dosage forms for oral transmucosal delivery of pharmaceutically active substances, and more particularly, to solid dosage forms producing higher dissolution rates and accordingly, higher absorption rates of the pharmaceutically active substance.
- the present invention provides improved solubility in saliva and mucosal absorption without compromising stability of the solid dosage form during storage.
- Solid pharmaceutical dosage forms are well known in the art. Compared to other dosage forms, such as solutions (oral or injection) and vapor or gas inhalation, the oral solid dosage forms are the most preferred dosage forms and they account for eighty percent of all the pharmaceutical products on the market. Solid dosage forms are easier for patient or caregiver to identify, handle and administer. They are also non-invasive and have high patient compliance.
- solid dosage forms can be further divided into several groups, gastrointestinal (GI) tract delivery, suppository (rectal, vaginal and urethral) delivery and oral transmucosal delivery.
- GI gastrointestinal
- suppository rectal, vaginal and urethral
- oral transmucosal delivery The majority of solid dosage forms on the market are designed for gastro-intestinal delivery. GI delivery is often referred to simply as "oral delivery.”
- Solids are also commonly delivered as suppositories such as laxatives, contraceptives and hemorrhoid medication.
- Relatively few drug formulations are designed as solid dosage forms intended to deliver a drug through the oral mucosa. Two such drug formulations are Oralet® and Actiq®.
- oral transmucosal (OT) delivery is a particularly advantageous delivery route.
- One of the advantages of OT delivery is that it is a non-invasive drug delivery method.
- OT delivery has better patient compliance, less risk of infection and lower cost than invasive procedures such as injection and implantation. It also has much shorter onset time, i.e., the time from administration to therapeutic effect, than does oral delivery.
- a drug absorbed via the oral mucosa will also avoid first pass metabolism, in which the drug is metabolized in the GI tract and liver.
- Oral transmucosal delivery is simple and can be administered by the caregiver or the patient with minimal discomfort.
- Transmucosal delivery of drugs is also accomplished through the use of patches which are attached using an adhesive to mucosal surfaces in the oral cavity.
- Oral transmucosal delivery using a buccal patch is disclosed in United States Patent No. 5,298,256 to Flockhart, et al.
- the buccal patch may be designed as a "closed" delivery system, that is, the environmental conditions inside the patch are primarily controlled by the formulation.
- Employing a closed delivery system can facilitate drug delivery, such as allowing the use of enhancers or other permeability facilitators in the formulation which might otherwise be impractical.
- the drug delivery conditions are influenced by the conditions of the surrounding environment, such as rate of saliva secretion, pH of the saliva, or other conditions beyond the control of the formulation.
- Buccal patch delivery also displays a pharmacokinetic delivery profile that can mimic a short term IV infusion.
- Solid dosage forms such as lozenges and tablets are commonly used for oral transmucosal delivery of pharmaceuticals.
- nitroglycerin sublingual tablets have been on the market for many years.
- the sublingual tablets are designed to deliver small amounts of the potent nitroglycerin, which is almost immediately dissolved and absorbed.
- most lozenges or tablets are typically designed to dissolve in the mouth over a period of at least several minutes which allows extended dissolution of the lozenge and absorption of the drug.
- a lozenge-on-a-stick dosage form of transmucosal drug delivery is disclosed in United States Patent No. 4,671,953 to Stanley, et al.
- the lozenge-on-a-stick dosage form allows a patient or caregiver to move the dose in and out of the mouth to titrate the dose.
- This practice is called dose-to-effect, in which a patient or caregiver controls the administration of the dose until the expected therapeutic effect is achieved.
- This is particularly important for certain symptoms, such as pain, nausea, motion sickness, and premedication prior to anesthesia because each patient needs a different amount of medication to treat these symptoms. For these types of treatments, the patient is the only one who knows how much medication is enough. Once the appropriate amount of drug is delivered, the patient or caregiver can remove the lozenge, thus, stopping the drug delivery to prevent overdose.
- Solid dosage units are made in a number of ways. In a high volume manufacturing facility, solid dosage units can be made by direct compression, injection molding, freeze-drying or other solid processing techniques. Compression, by far, is the most commonly used manufacturing process in making solid dosage units.
- a typical formulation of solid dosage form consists of active ingredient(s), bulking agent(s), binder(s), flavor(s), lubricant(s) and other excipients.
- solid dosage forms must be formulated to take into account the oral cavity's unique environment.
- the unique environment of the oral cavity can complicate the transmucosal delivery of the drug.
- one of the significant aspects of the oral cavity environment with regard to its use as a drug administration route is that there is relatively little solvent into which a solid dosage form can dissolve.
- the relative amounts of saliva produced in given circumstances can vary widely. On the average, salivary glands produce between 800 to 1500 ml saliva a day. In a resting, unstimulated state, salivary glands produce about 0.5 ml mucous-type saliva per minute, while stimulated salivary glands produce about 1 to 3 ml per minute. During the time required for solid dose drug delivery, about 10 to 15 minutes, the total amount of saliva produced is 10 to 15 ml, which is a small volume compared to 600 to 1000 ml of potential solvent produced in the GI tract.
- dA is the amount of drug delivered over time dt
- K p is the partition coefficient of the drug between oral mucosal tissue and the drug solution
- D is the diffusion coefficient of the drug inside the oral mucosal tissue
- S is the surface area of the oral cavity
- h is the thickness of the oral mucosal tissue
- C 2 are the drug concentrations in the solution and blood circulation, respectively.
- the capacity of the oral transmucosal delivery is limited in large part by the surface area available for drug absorption.
- the surface area in the oral cavity is 200 cm 2 , which is relatively small compared to the surface area of other drug delivery routes, such as the GI tract (350,000 cm 2 ) and skin (20,000 cm 2 ).
- the contact time between the drug and the absorption surface is primarily controlled by the dissolution rate of the solid unit. Once the solid unit is dissolved, any drug solution not yet absorbed will be swallowed, thereby ending further OT drug absorption. Generally the time a solid unit can remain in the oral cavity is between 10 to 15 minutes, but this time period is quite variable and depends upon a number of factors. Some of the factors affecting the contact time are difficult to account for, such as how vigorously a patient will suck on the dosage form.
- the solubility, the dissolution rate, and the partition coefficient determine the extent to which a drug can be delivered via the oral mucosal tissue.
- Solubility and dissolution rate are key aspects in creating the concentration gradient, which is the driving force for drug delivery.
- Partition coefficient acts like an amplifier, such that the drug delivery rate is directly proportional to the partition coefficient up to a point.
- the solubility of a drug is an inherent characteristic of the drug in a particular solvent. The relative affinities of the solute molecules and the solid phases determine the solubility.
- solubility of a drug is a specific thermodynamic property, that is, it describes the chemical state of the drug. Imbalance in a thermodynamic state will cause the change toward re-establishing a balance within the system. Because solubility is a specific thermodynamic quantity, any imbalance that causes a change away from solubility equilibrium will result in a change in the system toward re-establishing balance.
- the partition coefficient is the concentration ratio of a drug between two phases. Partition coefficient is determined largely by the inherent properties of the drug. In the case of oral transmucosal delivery, the attraction of drug molecules between two phases on the solution/tissue interface determines the partition coefficient of the drug. As with solubility, partition coefficient is a thermodynamic property and any imbalance will cause a change toward re-establishing a balanced state.
- the effectiveness of drug formulations is dependent upon the time frame imposed on the drug reaction.
- the dissolution rate of the drug unlike the solubility and partition coefficient, is a kinetic property of a drug.
- An otherwise effective drug may have a dissolution rate which is acceptable for one delivery method but which is too slow for the particular time frame of another.
- the dissolution rate of a drug may be acceptable for GI delivery, but the dissolution rate may not be practical for oral transmucosal delivery.
- the time frame in oral transmucosal delivery is 10 to 15 minutes rather than 4 to 6 hours in the GI tract.
- the physicochemical properties of a drug can be manipulated by changing the surrounding environment.
- the solubility of an ionizable drug can be greatly increased by changing the pH of the solution to a value at which the drug is in its ionized form.
- attempts to advantageously manipulate one particular physicochemical property can have a negative impact on another property.
- a pharmacist may attempt to increase the drug absorption by manipulating pH, but the altered pH negatively impacts other aspects of the formulation, such as the partition coefficient of the drug. Designing a solid, oral transmucosal formulation can be further complicated when a potentially effective solid formulation is unstable in storage and thereby rendered impractical for commercial use.
- Cyclodextrins for example, have been used in many formulations to increase the solubility of poorly soluble, hydrophobic drugs.
- Derivatized cyclodextrins are donut shaped molecules with a hydrophobic interior and hydrophilic exterior. Hydrophobic drugs can be sheltered inside the cyclodextrin cavity, and thus become soluble in the aqueous media.
- the weak acid or weak base can react with base or acid, respectively, to form a salt.
- the ionized salt forms will almost always have higher solubilities and dissolution rates than the unionized forms. In many cases, they are also more stable chemically or physically. However, the ionized forms almost always have lower partition coefficients than the unionized forms, and therefore are less well absorbed by the oral mucosal tissue. Thus, converting the weak acid or base to an ionized form in order to increase solubility compromises absorption.
- a common method of controlling the pH of the formulation is to use a buffer system.
- a buffer system consists of hydrogen ion donor(s) (acid) and conjugate hydrogen ion receiver(s) (base).
- An appropriate buffer system stabilizes the pH.
- optimizing the pH generally compromises the solubility and partition coefficient for oral transmucosal drug delivery.
- At least one embodiment of the present invention provides a method and formulation for oral transmucosal drug delivery of a solid that takes into account the unique environment of the oral cavity.
- At least one embodiment of the present invention provides a method and formulation for oral transmucosal delivery of a solid that allows for improved dissolution. Also, at least one embodiment of the present invention provides a method and formulation for oral transmucosal delivery of a solid that allows for improved stability of the formulation in storage.
- At least one embodiment of the present invention provides a method and formulation for oral transmucosal delivery of a solid that provides for increased absorption of the drug through the oral mucosal tissues. At lease one embodiment of the present invention provides a method and formulation for oral transmucosal delivery of a solid that allows for better control of dissolution of pharmaceutical agents.
- At least one embodiment of the present invention provides a method and formulation for oral transmucosal delivery of a solid that does not compromise stability in storage to improve absorption.
- the present invention comprises a pharmaceutical agent or drug which is capable of being absorbed into the tissues of the oral cavity or into the circulatory system through oral mucosal tissue.
- the pharmaceutical agent or drug is in solid form and is combined with a dissolution agent also in solid form, yielding a solid solution.
- the solid solution formulation maybe further combined with buffers and other excipients as needed in order to facilitate the drug's manufacturing, storage, administration and delivery through oral mucosal tissue.
- the formulation can be used with a variety of oral transmucosal delivery dosage forms, such as a tablet, lozenge, lozenge on a stick, chewing gum, and buccal or mucosal patch.
- the present invention is designed to work effectively in the unique environment of the oral cavity such that the limited amount of solvent, the relatively short period of time for drug delivery, and the pH levels within the oral cavity do not significantly deter absorption of the drug.
- the formulation is also designed to improve dissolution, solubility, and stability of the drug in solid solution. The advantages of the present invention contribute to the ability of the drug formulation to provide higher levels of drug absorption in oral transmucosal delivery.
- Figure 1 is a graph showing the serum drug concentration - time profile of piroxicam as delivered by the present invention compared to delivery using the prior art
- Figure 2 is a graph showing the plasma drug concentration - time profile of droperidol as delivered by the present invention compared to delivery using the prior art
- Figure 3 is a graph showing the serum drug concentration - time profile of etomidate as delivered by the present invention compared to delivery using the prior art.
- the present invention relates to novel methods and formulations for making solid dosage forms for oral transmucosal drug delivery. More specifically, the present invention relates to methods and formulations for making a solid solution formulation for oral transmucosal drug delivery.
- the present invention provides a number of advantages over the prior art formulations.
- the solid solution formulation comprises a pharmaceutical agent or drug capable of being delivered via the oral mucosal membrane and a dissolution agent(s) capable of being mixed with the pharmaceutical agent at the molecular level. Other pharmaceutical ingredients may be added to the formulation as necessary.
- the solid solution formulation provides for improved dissolution rate, solubility, and stability, and ultimately improved oral transmucosal drug delivery.
- the pharmaceutical agent of the present invention may be any drug substance, which is used for diagnosis, prevention, control, and treatment of physiological, pathological and psychological conditions. It is understood that a considerable variety of drug classes and specific drugs may be used as the pharmaceutical agent or agents of the present invention.
- the drug classes can include without limitation: androgens, estrogens, non-steroidal anti-inflammatory agents, anti-hypertensive agents, analgesic agents, anti- depressants, antibiotics, anti-cancer agents, local anesthetics, antiemetics, antiinfectants (antiinfectives), contraceptives, antidiabetic agents, steroids, antiallergy agents, antimigraine agents, agents for smoking cessation, and antiobesity agents.
- Specific drugs can include without limitation piroxicam, droperidol, etomidate, nicotine, testosterone, estradiol, nitroglycerin, clonidine, dexamethasone, wintergreen oil, tetracaine, lidocaine, fentanyl, sufentanil, progesterone, insulin, Vitamin A, Vitamin C, Vitamin E, prilocaine, bupivacaine, sumatriptan, dihydroergotamine, COX 2 inhibitors, and peptides.
- the selection of dissolution agent or agents will be determined by the pharmaceutical agent, as well as the process used in making the solid solution and characteristics of its intended use. (e.g., taste for OT delivery).
- a primary function of the dissolution agent is to combine with the pharmaceutical agent to form a solid solution. Therefore, the dissolution agent and the pharmaceutical agent must be able to mix at the molecular level. For example, if the co-melt process is used to make a solid solution, the dissolution agent must be capable of acting as a solvent into which the pharmaceutical agent can dissolve or melt. If a partial wet granulation process is used, the dissolution agent and the pharmaceutical agent must be able to dissolve in the proper solvent for this process.
- the dissolution agent may also enhance stability of the pharmaceutical agent. Since the dissolution agent is mixed with the pharmaceutical agent at the molecular level, it also provides a physical barrier for preventing the pharmaceutical agent from being contacted by other chemicals in the formulation or environment. For example, if the main degradation reaction of the pharmaceutical agent is hydrolysis, the use of a non- hygroscopic dissolution agent can block water from accessing the pharmaceutical agent. Therefore, the hydro lytic degradation reaction is prevented.
- the dissolution agents include but are not limited to acacia, alginic acid, carbomer, carboxymethylcellulose, calcium, carboxymethylcellulose sodium, microcrystalline cellulose, cellulose, dextrates, dextrin, dextrose, ethylcellulose, fructose, gelatin, guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactitol, lactose, lecithin, maltodextrin, mannitol, methylcellulose, poloxamer, polyethylene glycol, polymethacrylates, polyoxyethylene alkyl ethers, polyvinyl alcohol, povidone, propylene glycol alginate, sodium alginate, sodium ascorbate, sodium starch glycolate, sorbitol, starch, starch (pregelatinized), sucrose, tragacanth,
- a process of wet granulation is used to create the solid solution.
- the process of wet granulation can be outlined as several steps: weighing and blending of several ingredients in the presence of solvent(s), drying the mixture into solid, and milling the solid to proper size.
- the mixture is then dried and resized to powder so that it can be compressed into solid units.
- the mixture is then dried and resized to powder so that it can be compressed into solid units.
- Milling and screening steps are usually used to ensure the proper particle size distribution for compression.
- the wet-granulated powder may further be mixed with other ingredients to form the whole formulation.
- the formulation is made by a partial wet-granulation process.
- a formulation made using partial wet-granulation provides a unique opportunity for manufacturing ionizable compounds.
- the dissolution rate, solubility, stability and permeability of an ionizable drug are greatly influenced by the pH of the system.
- an ionized form of a drug has a higher dissolution rate and solubility, better stability, but lower permeability than does the unionized form.
- a partial wet granulation formulation can provide a special environment that facilitates the drug's dissolution in its local environment, yet controls the overall formulation to facilitate drug absorption.
- the key is the pH segregation in the solid formulation.
- the pH in wet granulated particles is adjusted so that the drug is ionized, i.e., low pH for a basic drug or high pH for an acidic drug.
- the pH in the whole formulation is adjusted so that the drug absorption is optimized.
- the drug is ionized and it is stable.
- the drug has a higher dissolution rate and solubility.
- the ionization of the drug is controlled by the overall environment, which is controlled by other constituents of the formulation.
- a process of co-melting is used to create the solid solution.
- the dissolution agent is heated and melted. In its melted state, the dissolution agent can act as a solvent into which the drug is dissolved or co-melted.
- the mixture of drug and dissolution agent is then cooled and solidified.
- the solid solution of drug and dissolution agent will be further processed into compressible powder.
- Other ingredients may also be added to the co-melted powder to complete the drug formulation, such as ingredients which allow additional pH manipulation.
- a process of freeze-drying is used to create the solid solution.
- the drug and dissolution agent are dissolved in aqueous solution.
- the solution is quickly frozen.
- the frozen solid is then put into a vacuum chamber where the water is removed from the solid via sublimation.
- the resulting powder is a solid solution of drug and dissolution agent.
- a process of spray-drying is used to create the solid solution. In this process, the drug and dissolution agent are dissolved in solution. The solution is then sprayed into a chamber. The solvent is evaporated while the droplets are in the air. The result is a fine powder consisting of drug and dissolution agent.
- the present invention provides for an increased dissolution rate of a drug using the solid solution in an oral transmucosal formulation. Because the drug is in the form of a solid solution, the dissolution rate is no longer determined by the characteristics of the drug itself, but by the dissolution profile of the solid solution. Since dissolution agents are usually selected because of their fast dissolution profiles, solid solution matrices usually dissolve quickly to release the drug in the oral cavity.
- the present invention provides a mechanism of controlling the drug dissolution and release by controlling the dissolution and disintegration rate of the solid unit.
- the present invention may also provide for a higher solubility for certain drugs by forming a supersaturated solution upon dissolving.
- the drug and dissolution agent in the form of a solid solution are mixed at the molecular level.
- the dissolution agents are usually selected based on their fast dissolution rate so that, upon dissolution of the dissolution agent, all the drug molecules will be in the solvent such that the drug concentration of the solution may exceed its solubility.
- a super saturated solution may exist until precipitation occurs.
- Precipitation can be viewed as three-step process: 1) the drug concentration in a solution becomes higher than its solubility; 2) drug nuclei form; and 3) the nuclei grows into crystals. More specifically, the drug concentration is a thermodynamic parameter and it determines whether crystals grow or dissolve.
- the concentration of the drug is higher than its solubility resulting in a solution that is supersaturated. Accordingly, the present invention provides a method of creating a supersaturated solution to improve the drug absorption.
- the present invention may also provide for a way to stabilize the drug in the solid formulation.
- the drug is processed and resides in micro-environment within the whole drug formulation, it is possible to create a favorable micro-environment to promote drug stability, and to promote absorption of the drug by using the rest of formulation to create a favorable environment for drug absorption.
- the solid solution drug formulation facilitates stability without compromising drug delivery.
- the segregated solid formulation is therefore a unique advantage of this invention.
- the drug incorporated within the dissolvable matrix be capable of permeating the mucosal membrane either alone or by suitable adjustments in the environmental pH, or other chemical modification or in combination with a suitable permeation enhancer.
- the present invention has applicability to a variety of drugs affecting the central nervous system.
- the present invention may easily be utilized in the administration of opioid agonists (such as fentanyl, alfentanil, sufentanil, lofentanil, and carfentanil), opioid antagonists (such as naloxone and nalbuphene), butyrophenones (such as droperidol and haloperidol); benzodiazepines (such as Valium, midazolam, triazolam, oxazolam, and lorazepam); GABA stimulators (such as etomidate); barbiturates (such as Thiopental, methohexital, thiamazol, pentobarbital, and hexabarbital); di-isopropylphenols drugs (such as diprivan); and other central nervous system-acting drugs such as levodopa.
- opioid agonists such as fentanyl, alfentan
- Table 1 lists some of the CNS-acting drugs which are suitable for incorporation into the present invention, as well as some of the characteristics of those drugs.
- Drugs having effects on the cardiovascular and renal vascular systems may also be administered using the present invention.
- a few examples of such drugs are identified in Table 2.
- certain macromolecular drugs such as .beta.-endorphin, enkephalins, bradykinin, aniotensin I, gonadotropic hormones, adrenocorticotropic hormone (ACTH), calcitonin, parathyroid hormone, and growth hormone
- polysaccharides such as heparin
- antigens antibodies, and enzymes
- ingredients that can be used in the formulation of the present invention may include, but are not limited to, absorbents, buffering agents (such as phosphate buffer, carbonate buffer, tris buffer, tartrate buffer, borate buffer, acetate buffer, or maleate buffer), colorants, flavorants, solvents and co-solvents, coating agents, direct compression excipients, disintegrants, glidants, lubricants, opaquants, polishing agents, suspending agents, sweetening agents, anti-adherents, binders, and capsule diluents, the ingredients may also include anti-fungal preservatives, antimicrobial preservatives, clarifying agents, emulsifying agents, antioxidants, levigating agents, plasticizers, surfactants, tonicity agents, and viscosity increasing agents.
- buffering agents such as phosphate buffer, carbonate buffer, tris buffer, tartrate buffer, borate buffer, acetate buffer, or maleate buffer
- colorants such as phosphate buffer, carbonate
- Example 1 In one actual experiment, oral transmucosal delivery of a pharmaceutical agent using the present invention was compared with oral transmucosal delivery of the same pharmaceutical agent using a prior art technique of physically mixing the drug formulation.
- the drug formulation included the ingredients piroxicam, mannitol, Emdex ® (dextrates, hydrated), sodium hydroxide, and magnesium stearate in the weight percentages and amounts per unit shown in Table A. TABLE A
- the physical mix formulation was prepared using a prior art method by (1) mixing all the ingredients except for magnesium stearate in a container, (2) mixing in magnesium stearate with the other ingredients, (3) compressing said ingredients with a Carver press at 3,000 psi.
- a process of wet granulation was used.
- the steps in this example included (1) mixing piroxicam, mannitol, sodium hydroxide and water, (2) drying the mixture in an oven at 40° centigrade for 48 hours to form a dried paste, (3) grinding the dried paste, (4) mixing the paste with the remaining ingredients except for magnesium stearate, (5) adding magnesium stearate and mixing again, and (6) compressing said ingredients with a carver press at 3,000 PSI.
- the physically mixed formulation (PM) and wet granulation formulation (WG) below, were administered oral transmucosally as part of an in vivo dog study. The results of the study are shown in Tables B-l and B-2 below as well as in Figure 1.
- Piroxicam Serum Concentration (ng/ml) After OT Delivery of Physical Mix Formulation in Dog Studies
- the data show an increase in both the maximum blood concentration, (C max ), and bioavailability (AUC).
- C max maximum blood concentration
- AUC bioavailability
- Example 2 In another experiment, the plasma concentrations of the drug droperidol delivered oral transmucosally using the present invention employing a co-melt technique were compared to those of droperidol delivered oral transmucosally using a prior art technique of physically mixing the drug formulation.
- the ingredients included droperidol, polyethylene glycol, citric acid in sorbitol, and solvent. The ingredients were mixed in the amounts shown in Table C.
- the prior art formulation was prepared by physically mixing the ingredients and compressing them into solid units.
- the present invention formulation was prepared by heating droperidol and PEG in a 90° C water bath until the PEG was melted. The mixture was then cooled, solidified, and milled into powder. The co-melt powder was mixed with the other ingredients and compressed into solid units.
- the pharmaceutical agents were delivered oral transmucosally as part of an in vivo dog study.
- the blood plasma drug concentrations (Table D) of the subjects were measured over a period of 6 hours. TABLE D
- Example 3 In yet another experiment employing the co-melt process, the oral transmucosal delivery of the drug etomidate using the present invention was compared with delivery using prior art methods.
- the drug formulations were prepared using the ingredients Etomidate, PEG and Sorbitol. The amounts of each ingredient in the formulations are shown in Table E. TABLE E
- the prior art formulation was prepared using a process of physical mixing.
- the present invention formulation was prepared using a co-melting process to create a solid solution containing etomidate.
- the two formulations were administered oral transmucosally as part of an in vivo dog study. Serum concentrations of the drug were measured over a 90 minute period. The results are shown in Tables F-1 and F-2 and in Figure 3.
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA02004235A MXPA02004235A (en) | 1999-10-27 | 2000-10-12 | Oral transmucosal drug dosage using solid solution. |
JP2001532709A JP4815084B2 (en) | 1999-10-27 | 2000-10-12 | Oral transmucosal drug dosage form using solid solution |
AU10797/01A AU1079701A (en) | 1999-10-27 | 2000-10-12 | Oral transmucosal drug dosage using solid solution |
AT00972083T ATE468845T2 (en) | 1999-10-27 | 2000-10-12 | BUCCAL TRANSMUCOSAL DRUG DELIVERY USING A SOLID SOLUTION |
ES00972083.0T ES2345870T5 (en) | 1999-10-27 | 2000-10-12 | Dosage of oral transmucosal drugs using a solid solution |
DE60044464T DE60044464D1 (en) | 1999-10-27 | 2000-10-12 | BUKKALE TRANSMUCOSAL DRUG CLEANING USING A SOLID SOLUTION |
EP00972083.0A EP1242013B2 (en) | 1999-10-27 | 2000-10-12 | Oral transmucosal drug dosage using solid solution |
CA002388610A CA2388610C (en) | 1999-10-27 | 2000-10-12 | Oral transmucosal drug dosage using solid solution |
HK03102146.6A HK1050313A1 (en) | 1999-10-27 | 2003-03-25 | Oral transmucosal drug dosage using solid solution |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/428,071 | 1999-10-27 | ||
US09/428,071 US6264981B1 (en) | 1999-10-27 | 1999-10-27 | Oral transmucosal drug dosage using solid solution |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001030288A1 true WO2001030288A1 (en) | 2001-05-03 |
Family
ID=23697434
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/028113 WO2001030288A1 (en) | 1999-10-27 | 2000-10-12 | Oral transmucosal drug dosage using solid solution |
Country Status (12)
Country | Link |
---|---|
US (1) | US6264981B1 (en) |
EP (1) | EP1242013B2 (en) |
JP (2) | JP4815084B2 (en) |
AT (1) | ATE468845T2 (en) |
AU (1) | AU1079701A (en) |
CA (1) | CA2388610C (en) |
DE (1) | DE60044464D1 (en) |
ES (1) | ES2345870T5 (en) |
HK (1) | HK1050313A1 (en) |
MX (1) | MXPA02004235A (en) |
PT (1) | PT1242013E (en) |
WO (1) | WO2001030288A1 (en) |
Cited By (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004041239A1 (en) * | 2002-11-08 | 2004-05-21 | Lts Lohmann Therapie-Systeme Ag | Transmucosal pharmaceutical administration form |
WO2004069198A2 (en) * | 2003-02-04 | 2004-08-19 | Cephalon, Inc. | Sugar-free oral transmucosal solid dosage forms and uses thereof |
DE102005003387A1 (en) * | 2004-09-01 | 2006-03-02 | LABTEC Gesellschaft für technologische Forschung und Entwicklung mbH | Plaster for administering active agents through body orifices, comprises adhesive and backing layers, both made of nonionic and anionic hydrocolloids in reverse ratios |
JP2006513238A (en) * | 2002-12-19 | 2006-04-20 | ファルマシア・コーポレーション | Non-hygroscopic formulations containing hygroscopic drugs |
JP2006519187A (en) * | 2003-02-28 | 2006-08-24 | アルカベロ アクチェセルスカプ | Dosage form with saccharide matrix |
WO2007009801A3 (en) * | 2005-07-20 | 2007-06-21 | Hexal Ag | Oral, quickly disintegrating film, which cannot be spit out, for a neuroleptic drug |
EP1803443A2 (en) * | 2002-12-20 | 2007-07-04 | NicoNovum AB | A method for the preparation of a nicotine-containing particulate material with a crystalline cellulose (in particular MCC) |
WO2007085498A1 (en) * | 2006-01-24 | 2007-08-02 | Bayer Schering Pharma Aktiengesellschaft | Pharmaceutical forms in film form for use in the mouth (wafers) |
WO2007133141A1 (en) * | 2006-05-16 | 2007-11-22 | Mcneil Ab | Coated pharmaceutical product for intraoral delivery of nicotine comprising trometamol as buffering agent |
WO2007133140A1 (en) * | 2006-05-16 | 2007-11-22 | Mcneil Ab | Pharmaceutical product for intraoral delivery of nicotine comprising trometamol as buffering agent |
WO2008011194A2 (en) * | 2006-07-21 | 2008-01-24 | Biodelivery Sciences International, Inc. | Transmucosal delivery devices with enhanced uptake |
WO2008011177A2 (en) * | 2006-07-21 | 2008-01-24 | Jsrnti, Llc | Medicinal delivery system and related methods |
WO2008085765A3 (en) * | 2007-01-05 | 2008-11-27 | Acelrx Pharmaceuticals Inc | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
EP2308476A1 (en) * | 2003-11-19 | 2011-04-13 | Inkine Pharmaceutical Company, Inc. | Colonic purgative composition with soluble binding agent |
WO2011047143A1 (en) * | 2009-10-16 | 2011-04-21 | Acelrx Pharmaceuticals, Inc. | Compositions and methods for mild sedation, anxiolysis and analgesia in the procedural setting |
US8012505B2 (en) | 2003-02-28 | 2011-09-06 | Alk-Abello A/S | Dosage form having a saccharide matrix |
US8202535B2 (en) | 2006-01-06 | 2012-06-19 | Acelrx Pharmaceuticals, Inc. | Small-volume oral transmucosal dosage forms |
WO2013041851A1 (en) | 2011-09-19 | 2013-03-28 | Orexo Ab | New abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
US8535714B2 (en) | 2006-01-06 | 2013-09-17 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
US8652378B1 (en) | 2001-10-12 | 2014-02-18 | Monosol Rx Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
AU2012202628B2 (en) * | 2003-11-19 | 2014-05-15 | Salix Pharmaceuticals, Inc. | Colonic purgative composition with soluble binding agent |
US8765167B2 (en) | 2001-10-12 | 2014-07-01 | Monosol Rx, Llc | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
US8815911B2 (en) | 2012-05-02 | 2014-08-26 | Orexo Ab | Alfentanil composition for the treatment of acute pain |
US8865211B2 (en) | 2006-01-06 | 2014-10-21 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
US8865202B2 (en) | 1996-11-11 | 2014-10-21 | Lts Lohmann Therapie-Systeme Ag | Water soluble film for oral administration with instant wettability |
US8900497B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for making a film having a substantially uniform distribution of components |
US8900498B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for manufacturing a resulting multi-layer pharmaceutical film |
US8906277B2 (en) | 2001-10-12 | 2014-12-09 | Monosol Rx, Llc | Process for manufacturing a resulting pharmaceutical film |
US8905964B2 (en) | 2006-01-06 | 2014-12-09 | Acelrx Pharmaceuticals, Inc. | Drug storage and dispensing devices and systems comprising the same |
US8945592B2 (en) | 2008-11-21 | 2015-02-03 | Acelrx Pharmaceuticals, Inc. | Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same |
US9023393B2 (en) | 2003-08-04 | 2015-05-05 | Bend Research, Inc. | Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials |
US9066847B2 (en) | 2007-01-05 | 2015-06-30 | Aceirx Pharmaceuticals, Inc. | Storage and dispensing devices for administration of oral transmucosal dosage forms |
US9108340B2 (en) | 2001-10-12 | 2015-08-18 | Monosol Rx, Llc | Process for manufacturing a resulting multi-layer pharmaceutical film |
US9289583B2 (en) | 2006-01-06 | 2016-03-22 | Acelrx Pharmaceuticals, Inc. | Methods for administering small volume oral transmucosal dosage forms using a dispensing device |
US9320721B2 (en) | 2004-09-01 | 2016-04-26 | Tesa Labtec Gmbh | Mucoadhesive patch with opposite ratios of nonionic and anionic hydrocolloids in adhesive and backing layer |
CN101621994B (en) * | 2007-01-05 | 2016-06-01 | 阿塞尔Rx制药有限公司 | For treating a small amount of oral transmucosal dosage forms containing sufentanil of pain |
US9468604B2 (en) | 2001-06-22 | 2016-10-18 | Bend Research, Inc. | Pharmaceutical compositions of dispersions of drug and neutral polymers |
US9486410B2 (en) | 2002-02-01 | 2016-11-08 | Bend Research, Inc. | Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials |
AU2015221520B2 (en) * | 2003-11-19 | 2017-06-08 | Salix Pharmaceuticals, Inc. | Colonic purgative composition with soluble binding agent |
US9901539B2 (en) | 2011-12-21 | 2018-02-27 | Biodelivery Sciences International, Inc. | Transmucosal drug delivery devices for use in chronic pain relief |
US10219999B2 (en) | 2006-03-16 | 2019-03-05 | Niconovum Usa, Inc. | Snuff composition |
US10272607B2 (en) | 2010-10-22 | 2019-04-30 | Aquestive Therapeutics, Inc. | Manufacturing of small film strips |
US10285910B2 (en) | 2001-10-12 | 2019-05-14 | Aquestive Therapeutics, Inc. | Sublingual and buccal film compositions |
US10821074B2 (en) | 2009-08-07 | 2020-11-03 | Aquestive Therapeutics, Inc. | Sublingual and buccal film compositions |
US11077068B2 (en) | 2001-10-12 | 2021-08-03 | Aquestive Therapeutics, Inc. | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
US11191737B2 (en) | 2016-05-05 | 2021-12-07 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine compositions |
US11207805B2 (en) | 2001-10-12 | 2021-12-28 | Aquestive Therapeutics, Inc. | Process for manufacturing a resulting pharmaceutical film |
US11273131B2 (en) | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
US11737980B2 (en) | 2020-05-18 | 2023-08-29 | Orexo Ab | Pharmaceutical composition for drug delivery |
WO2023187664A1 (en) * | 2022-03-30 | 2023-10-05 | Avaca Pharma Private Limited | A pharmaceutical composition for the treatment of immune system mediated diseases |
US11957647B2 (en) | 2021-11-25 | 2024-04-16 | Orexo Ab | Pharmaceutical composition comprising adrenaline |
Families Citing this family (202)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7153845B2 (en) * | 1998-08-25 | 2006-12-26 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
US8765177B2 (en) * | 1997-09-12 | 2014-07-01 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
US20030091629A1 (en) * | 1998-03-27 | 2003-05-15 | Cima Labs Inc. | Sublingual buccal effervescent |
US6350470B1 (en) | 1998-04-29 | 2002-02-26 | Cima Labs Inc. | Effervescent drug delivery system for oral administration |
US6974590B2 (en) * | 1998-03-27 | 2005-12-13 | Cima Labs Inc. | Sublingual buccal effervescent |
US6576250B1 (en) | 1998-03-27 | 2003-06-10 | Cima Labs Inc. | Pharmaceutical compositions for rectal and vaginal administration |
US20030118645A1 (en) * | 1998-04-29 | 2003-06-26 | Pather S. Indiran | Pharmaceutical compositions for rectal and vaginal administration |
US20020098264A1 (en) * | 1998-11-27 | 2002-07-25 | Cherukuri Subraman R. | Medicated chewing gum delivery system for nicotine |
US6358060B2 (en) * | 1998-09-03 | 2002-03-19 | Jsr Llc | Two-stage transmucosal medicine delivery system for symptom relief |
US8188043B2 (en) * | 1999-07-28 | 2012-05-29 | The Board Of Trustees Of The Leland Stanford Jr. University | Nicotine in therapeutic angiogenesis and vasculogenesis |
GB0001710D0 (en) * | 2000-01-25 | 2000-03-15 | Pharma Pacific Pty Ltd | Therapeutic treatment |
GB2359747B (en) * | 2000-02-29 | 2002-04-24 | Maelor Pharmaceuticals Ltd | Anaesthetic formulations |
DE10026698A1 (en) | 2000-05-30 | 2001-12-06 | Basf Ag | Self-emulsifying active ingredient formulation and use of this formulation |
USRE44145E1 (en) | 2000-07-07 | 2013-04-09 | A.V. Topchiev Institute Of Petrochemical Synthesis | Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties |
US7749540B2 (en) * | 2000-10-11 | 2010-07-06 | Cephalon, Inc. | Compositions comprising modafinil compounds |
EP1390084B1 (en) | 2001-05-01 | 2011-03-23 | A.V. Topchiev Institute of Petrochemical Synthesis | Two-phase, water-absorbent bioadhesive composition |
US8206738B2 (en) | 2001-05-01 | 2012-06-26 | Corium International, Inc. | Hydrogel compositions with an erodible backing member |
US8541021B2 (en) | 2001-05-01 | 2013-09-24 | A.V. Topchiev Institute Of Petrochemical Synthesis | Hydrogel compositions demonstrating phase separation on contact with aqueous media |
US20050215727A1 (en) | 2001-05-01 | 2005-09-29 | Corium | Water-absorbent adhesive compositions and associated methods of manufacture and use |
US8840918B2 (en) | 2001-05-01 | 2014-09-23 | A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences | Hydrogel compositions for tooth whitening |
EP1390085B1 (en) | 2001-05-01 | 2009-08-05 | A.V. Topchiev Institute of Petrochemical Synthesis | Hydrogel compositions |
US20050113510A1 (en) | 2001-05-01 | 2005-05-26 | Feldstein Mikhail M. | Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components |
CA2447444A1 (en) * | 2001-05-11 | 2002-11-21 | Orasense, Ltd. | Antisense permeation enhancers |
SE521512C2 (en) * | 2001-06-25 | 2003-11-11 | Niconovum Ab | Device for administering a substance to the front of an individual's oral cavity |
US20030068356A1 (en) * | 2001-07-10 | 2003-04-10 | Pather S. Indiran | Sequential drug delivery systems |
DE10141650C1 (en) | 2001-08-24 | 2002-11-28 | Lohmann Therapie Syst Lts | Safe transdermal therapeutic system for administration of fentanyl or analogous analgesics, having matrix layer of carboxy group-free polyacrylate adhesive providing high permeation rate |
US7854230B2 (en) * | 2001-10-22 | 2010-12-21 | O.R. Solutions, Inc. | Heated medical instrument stand with surgical drape and method of detecting fluid and leaks in the stand tray |
DE60138494D1 (en) * | 2001-11-29 | 2009-06-04 | Rettenmaier & Soehne Gmbh & Co | PROCESS FOR CO-SPRAY DRYING LIQUID HERB EXTRACTS WITH DRY SILIFIED MCC |
GB0129117D0 (en) * | 2001-12-05 | 2002-01-23 | Glaxo Group Ltd | Pharmaceutical composition |
US20030159702A1 (en) * | 2002-01-21 | 2003-08-28 | Lindell Katarina E.A. | Formulation and use manufacture thereof |
JP3931680B2 (en) * | 2002-02-18 | 2007-06-20 | 株式会社日本自動車部品総合研究所 | Straight traveling discrimination device for vehicle |
US8017150B2 (en) * | 2002-04-11 | 2011-09-13 | Monosol Rx, Llc | Polyethylene oxide-based films and drug delivery systems made therefrom |
GB0210397D0 (en) * | 2002-05-07 | 2002-06-12 | Ferring Bv | Pharmaceutical formulations |
EP1575487B1 (en) | 2002-05-14 | 2019-08-14 | DuPont Nutrition USA, Inc. | Coattrited microcrystalline cellulose hydrocolloid compositions and method for manufacture |
GB0217056D0 (en) * | 2002-07-23 | 2002-08-28 | Ass Octel | Use |
KR100548925B1 (en) * | 2002-10-23 | 2006-02-02 | 한미약품 주식회사 | Sustained release composition for oral administration of a drug |
US20080213363A1 (en) * | 2003-01-23 | 2008-09-04 | Singh Nikhilesh N | Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa |
US9254294B2 (en) | 2003-02-24 | 2016-02-09 | Pharmaceutical Productions Inc. | Transmucosal hormone delivery system |
US10172810B2 (en) | 2003-02-24 | 2019-01-08 | Pharmaceutical Productions, Inc. | Transmucosal ketamine delivery composition |
US9358296B2 (en) | 2003-02-24 | 2016-06-07 | Pharmaceutical Productions Inc. | Transmucosal drug delivery system |
KR101170844B1 (en) | 2003-02-24 | 2012-08-02 | 파마슈티칼 프로덕션스, 인크. | Transmucosal drug delivery system |
US9498454B2 (en) | 2003-02-24 | 2016-11-22 | Pharmaceutical Productions Inc. | Transmucosal drug delivery system |
US7648981B2 (en) * | 2003-02-28 | 2010-01-19 | Ym Biosciences Inc. | Opioid delivery system |
US7648982B2 (en) * | 2003-02-28 | 2010-01-19 | Ym Biosciences Inc. | Opioid delivery system |
US20050137265A1 (en) * | 2003-03-31 | 2005-06-23 | Haley Eugene T. | Rapidly dissolving metoclopramide solid oral dosage and method thereof |
US20040192781A1 (en) * | 2003-03-31 | 2004-09-30 | Haley Eugene T. | Method of administration for metoclopramide and pharmaceutical formulation therefor |
US20040202717A1 (en) | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
US20040213828A1 (en) * | 2003-04-23 | 2004-10-28 | Smith David J. | Pain relief lollipop compositions and methods |
SG173919A1 (en) * | 2003-04-23 | 2011-09-29 | Medarex Inc | Compositions and methods for the therapy of inflammatory bowel disease |
AU2004233997C1 (en) | 2003-04-29 | 2014-01-30 | Massachusetts Institiute Of Technology | Methods and devices for the sustained release of multiple drugs |
US7306812B2 (en) | 2003-05-09 | 2007-12-11 | Cephalon, Inc. | Dissolvable backing layer for use with a transmucosal delivery device |
US7276246B2 (en) * | 2003-05-09 | 2007-10-02 | Cephalon, Inc. | Dissolvable backing layer for use with a transmucosal delivery device |
WO2005004989A2 (en) * | 2003-07-01 | 2005-01-20 | Todd Maibach | Film comprising therapeutic agents |
ES2654062T3 (en) * | 2003-07-24 | 2018-02-12 | Glaxosmithkline Llc | Oral Dissolution Films |
US20050037194A1 (en) * | 2003-08-15 | 2005-02-17 | Kimberly-Clark Worldwide, Inc. | Thermoplastic polymers with thermally reversible and non-reversible linkages, and articles using same |
US20050042281A1 (en) * | 2003-08-21 | 2005-02-24 | Singh Nikhilesh N. | Compositions for delivering therapeutic agents across the oral mucosa |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
GB0320854D0 (en) * | 2003-09-05 | 2003-10-08 | Arrow No 7 Ltd | Buccal drug delivery |
US20050065175A1 (en) * | 2003-09-24 | 2005-03-24 | Xanodyne Pharmacal, Inc. | Oral transmucosal methadone |
US8627828B2 (en) | 2003-11-07 | 2014-01-14 | U.S. Smokeless Tobacco Company Llc | Tobacco compositions |
AU2004289248B2 (en) | 2003-11-07 | 2012-05-03 | U.S. Smokeless Tobacco Company Llc | Tobacco compositions |
DK1530967T3 (en) * | 2003-11-13 | 2006-07-03 | Ferring Bv | Blister pack and associated solid dosage form |
WO2005065317A2 (en) | 2003-12-31 | 2005-07-21 | Cima Labs Inc. | Effervescent oral fentanyl dosage form |
EP1708685B1 (en) * | 2003-12-31 | 2011-03-09 | Cima Labs Inc. | Effervescent oral opiate dosage forms and methods of administering oxycodone |
EP1701704A2 (en) * | 2003-12-31 | 2006-09-20 | Pfizer Products Inc. | Solid compositions of low-solubility drugs and poloxamers |
BRPI0418228B8 (en) * | 2003-12-31 | 2021-05-25 | Cima Labs Inc | dosage form, and method of preparing a tablet for buccal, gingival or sublingual administration of fentanyl |
BRPI0418294A (en) * | 2003-12-31 | 2007-05-02 | Pfizer Prod Inc | stabilized solid pharmaceutical compositions of low solubility drugs, poloxamers and stabilizing polymers |
WO2005072803A1 (en) * | 2004-01-16 | 2005-08-11 | Biodel, Inc. | Sublingual drug delivery device |
WO2005074894A1 (en) * | 2004-01-30 | 2005-08-18 | Corium International | Rapidly dissolving film for delivery of an active agent |
KR20130006523A (en) | 2004-02-17 | 2013-01-16 | 트랜스셉트 파마슈티칼스, 인코포레이티드 | Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof |
US20080090753A1 (en) * | 2004-03-12 | 2008-04-17 | Biodel, Inc. | Rapid Acting Injectable Insulin Compositions |
PT2319500E (en) * | 2004-03-12 | 2013-01-23 | Biodel Inc | Rapid acting drug delivery compositions |
US20080096800A1 (en) * | 2004-03-12 | 2008-04-24 | Biodel, Inc. | Rapid mucosal gel or film insulin compositions |
US20050226906A1 (en) * | 2004-04-08 | 2005-10-13 | Micro Nutrient, Llc | Nutrient system for individualized responsive dosing regimens |
US7850987B2 (en) * | 2004-04-08 | 2010-12-14 | Micronutrient, Llc | Nutrient composition(s) and system(s) for individualized, responsive dosing regimens |
US7785619B2 (en) * | 2004-04-08 | 2010-08-31 | Micro Nutrient, Llc | Pharmanutrient composition(s) and system(s) for individualized, responsive dosing regimens |
PL1750862T3 (en) | 2004-06-04 | 2011-06-30 | Teva Pharma | Pharmaceutical composition containing irbesartan |
KR20150041193A (en) * | 2004-06-21 | 2015-04-15 | 메다렉스, 엘.엘.시. | Interferon alpha receptor 1 antibodies and their uses |
MX2007001512A (en) | 2004-08-05 | 2007-04-20 | Corium Int Inc | Adhesive composition. |
JP2008511607A (en) * | 2004-08-31 | 2008-04-17 | ファイザー・プロダクツ・インク | Pharmaceutical dosage form comprising a low-solubility drug and a polymer |
US20060051413A1 (en) * | 2004-09-08 | 2006-03-09 | Chow Sing S M | Method of enhancing absorptions of transmucosal administration formulations |
CN101098679A (en) * | 2004-11-05 | 2008-01-02 | 国王医药研究与发展有限公司 | Stabilized ramipril compositions and methods of making |
US9198448B2 (en) * | 2005-02-07 | 2015-12-01 | Intercontinental Great Brands Llc | Stable tooth whitening gum with reactive ingredients |
DE102005015128B4 (en) * | 2005-03-31 | 2008-12-11 | Bayer Schering Pharma Aktiengesellschaft | Wafers containing steroid hormones |
KR20080031208A (en) * | 2005-05-25 | 2008-04-08 | 트랜스셉트 파마슈티칼스, 인코포레이티드 | Solid compositions and methods for treating middle-of-the night insomnia |
US20070287740A1 (en) * | 2005-05-25 | 2007-12-13 | Transcept Pharmaceuticals, Inc. | Compositions and methods of treating middle-of-the night insomnia |
US20070225322A1 (en) * | 2005-05-25 | 2007-09-27 | Transoral Pharmaceuticals, Inc. | Compositions and methods for treating middle-of-the night insomnia |
US8202534B2 (en) * | 2005-06-03 | 2012-06-19 | Teva Women's Health, Inc. | Attachment of a handle to a solid oral dosage form |
US20070020186A1 (en) | 2005-07-22 | 2007-01-25 | Alpex Pharma S.A. | Solid dosage formulations of narcotic drugs having improved buccal adsorption |
US9877921B2 (en) | 2005-09-09 | 2018-01-30 | Nova Southeastern University | Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine |
WO2014007972A2 (en) | 2012-06-15 | 2014-01-09 | Nova Southeastern University | Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinphrine |
US20160045457A1 (en) | 2005-09-09 | 2016-02-18 | Ousama Rachid | Epinephrine fine particles and methods for use thereof for treatment of conditions responsive to epinephrine |
US20070059361A1 (en) * | 2005-09-09 | 2007-03-15 | University Of Manitoba | Fast-disintegrating epinephrine tablets for buccal or sublingual administration |
US7713929B2 (en) | 2006-04-12 | 2010-05-11 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
US8084420B2 (en) * | 2005-09-29 | 2011-12-27 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
US7879382B2 (en) * | 2005-09-30 | 2011-02-01 | Fmc Corporation | Stabilizers and compositions and products comprising same |
US20070104763A1 (en) * | 2005-11-10 | 2007-05-10 | Navinta Llc | Composition of fentanyl citrate oral solid transmucosal dosage form, excipient and binding material therefore, and methods of making |
US8252328B2 (en) * | 2006-01-06 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
US8753308B2 (en) | 2006-01-06 | 2014-06-17 | Acelrx Pharmaceuticals, Inc. | Methods for administering small volume oral transmucosal dosage forms using a dispensing device |
CN106727271B (en) * | 2006-01-06 | 2020-02-14 | 阿塞尔Rx制药有限公司 | Small volume oral transmucosal dosage form |
US20070172507A1 (en) * | 2006-01-26 | 2007-07-26 | Paul Zupkas | Transluminal drug delivery methods and devices |
US7718609B2 (en) * | 2006-04-12 | 2010-05-18 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
US20070260491A1 (en) * | 2006-05-08 | 2007-11-08 | Pamela Palmer | System for delivery and monitoring of administration of controlled substances |
WO2007143674A2 (en) * | 2006-06-05 | 2007-12-13 | Verus Pharmaceuticals, Inc. | Methods for buccal, lingual or sublingual dosing regimens of epinephrine for the treatment of allergic emergencies |
WO2007143676A2 (en) * | 2006-06-05 | 2007-12-13 | Verus Pharmaceuticals, Inc. | Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms |
DE102006027796A1 (en) * | 2006-06-16 | 2007-12-20 | Lts Lohmann Therapie-Systeme Ag | Flat form medicament preparation based on hydrophilic polymer disintegrates quickly in contact with moisture, useful e.g. to release active agent in body opening/body cavity e.g. for contraception, comprises active agent combination |
US20070299687A1 (en) * | 2006-06-23 | 2007-12-27 | Pamela Palmer | Inpatient system for patient-controlled delivery of oral transmucosal medications dosed as needed |
JP2010507676A (en) * | 2006-10-27 | 2010-03-11 | エフ エム シー コーポレーション | Dry granulating binder, product and use thereof |
EP2112923A1 (en) | 2007-01-22 | 2009-11-04 | Targacept Inc. | Intranasal, buccal, and sublingual administration of metanicotine analogs |
US20100215774A1 (en) * | 2007-02-09 | 2010-08-26 | Todd Maibach | Film comprising nitroglycerin |
US20100010031A1 (en) * | 2007-02-09 | 2010-01-14 | Yum Ii Su | Transoral dosage forms comprising sufentanil and naloxone |
KR20090129998A (en) | 2007-02-11 | 2009-12-17 | 맵 파마슈티컬스, 인코포레이티드 | Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile |
WO2008124522A2 (en) * | 2007-04-04 | 2008-10-16 | Biodel, Inc. | Amylin formulations |
WO2008124928A1 (en) * | 2007-04-13 | 2008-10-23 | Christopher Culligan | Freezable unit dosage delivery system and method of preparation |
US20100260690A1 (en) * | 2007-09-18 | 2010-10-14 | Arne Kristensen | Stable chewing gum compositions comprising maltitol and providing rapid release of nicotine |
CN101951957A (en) * | 2008-01-04 | 2011-01-19 | 百达尔公司 | Insulin discharges the insulin preparation as the function of the glucose level of tissue |
US8137690B2 (en) | 2008-01-17 | 2012-03-20 | Health Innovations, Llc | Taste titration therapies |
US20110082150A1 (en) * | 2008-02-11 | 2011-04-07 | Robert Owen Cook | Headache pre-emption by dihydroergotamine treatment during headache Precursor events |
CA2714340A1 (en) * | 2008-02-13 | 2009-08-20 | Bayer Schering Pharma Aktiengesellschaft | Estradiol-containing drug delivery system |
NZ587309A (en) * | 2008-02-13 | 2012-09-28 | Bayer Schering Pharma Ag | Wafer film systems for for the delivery of estrogen or progestin |
AU2009240586A1 (en) * | 2008-04-24 | 2009-10-29 | Evestra, Inc. | Oral contraceptive dosage forms comprising a progestogen dispersed in an enteric polymer and further comprising an estrogen |
US20090298946A1 (en) * | 2008-06-02 | 2009-12-03 | Cleavelin Cody R | Local Anesthetic Deactivation |
CA2728912C (en) * | 2008-06-23 | 2018-04-10 | Biodelivery Sciences International, Inc. | Multidirectional mucosal delivery devices and methods of use |
WO2010031552A1 (en) * | 2008-09-17 | 2010-03-25 | Niconovum Ab | Process for preparing snuff composition |
WO2010147981A1 (en) | 2009-06-18 | 2010-12-23 | Allergan, Inc. | Safe desmopressin administration |
EP2387394B1 (en) | 2009-01-14 | 2018-05-02 | Corium International, Inc. | Transdermal administration of tamsulosin |
US9060927B2 (en) * | 2009-03-03 | 2015-06-23 | Biodel Inc. | Insulin formulations for rapid uptake |
ES2554626T3 (en) | 2009-06-12 | 2015-12-22 | Cynapsus Therapeutics Inc. | Sublingual apomorphine |
US8475832B2 (en) | 2009-08-07 | 2013-07-02 | Rb Pharmaceuticals Limited | Sublingual and buccal film compositions |
US9125858B2 (en) | 2009-11-30 | 2015-09-08 | Wilmore Labs L.L.C. | Compositions and methods relating to resveratrol |
US20120322884A1 (en) | 2010-03-01 | 2012-12-20 | University Of Manitoba | Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine |
EP2591774B1 (en) | 2010-07-09 | 2020-05-27 | Teijin Pharma Limited | Orally disintegrating tablet |
US9504664B2 (en) | 2010-10-29 | 2016-11-29 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
US9744132B2 (en) | 2010-10-29 | 2017-08-29 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
US10695431B2 (en) * | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
US11224659B2 (en) | 2010-10-29 | 2022-01-18 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
US9737500B2 (en) | 2010-10-29 | 2017-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
US10695432B2 (en) * | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
US11730709B2 (en) | 2010-10-29 | 2023-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
US8895536B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating chronic inflammation and inflammatory diseases |
US9271950B2 (en) | 2010-10-29 | 2016-03-01 | Infirst Healthcare Limited | Compositions for treating chronic inflammation and inflammatory diseases |
US11202831B2 (en) | 2010-10-29 | 2021-12-21 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
US9308213B2 (en) | 2010-10-29 | 2016-04-12 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
ES2791715T3 (en) | 2010-12-16 | 2020-11-05 | Sunovion Pharmaceuticals Inc | Sublingual Movies |
SI2701681T1 (en) | 2011-04-29 | 2017-01-31 | Moberg Pharma Ab | Pharmaceutical compositions comprising a local anaesthetic such as bupivacaine for local administration to the mouth or throat |
US9925264B2 (en) | 2011-05-10 | 2018-03-27 | Itochu Chemical Frontier Corporation | Non-aqueous patch |
WO2012153396A1 (en) | 2011-05-10 | 2012-11-15 | 伊藤忠ケミカルフロンティア株式会社 | Non-aqueous patch |
US11786455B2 (en) | 2011-05-10 | 2023-10-17 | Itochu Chemical Frontier Corporation | Non-aqueous patch |
US9474303B2 (en) | 2011-09-22 | 2016-10-25 | R.J. Reynolds Tobacco Company | Translucent smokeless tobacco product |
US9084439B2 (en) | 2011-09-22 | 2015-07-21 | R.J. Reynolds Tobacco Company | Translucent smokeless tobacco product |
US9629392B2 (en) | 2011-09-22 | 2017-04-25 | R.J. Reynolds Tobacco Company | Translucent smokeless tobacco product |
US20130078307A1 (en) | 2011-09-22 | 2013-03-28 | Niconovum Usa, Inc. | Nicotine-containing pharmaceutical composition |
EP2572731A1 (en) * | 2011-09-26 | 2013-03-27 | Abbott GmbH & Co. KG | Formulations based on solid dispersions |
TR201810942T4 (en) | 2011-09-27 | 2018-09-21 | Itochu Chemical Frontier Corp | Waterless tape. |
BR112014007366B1 (en) | 2011-10-05 | 2020-09-15 | Dupont Nutrition Usa, Inc | PROCESS FOR MANUFACTURING A STABILIZING COMPOSITION UNDERSTANDING TWO-STEP EXTRUSION, STABILIZING COMPOSITION OF MICRO CRYSTALLINE CELLULOSE AND EDIBLE FOOD AND INDUSTRIAL SUSPENSION UNDERSTANDING THE SAME |
US9055757B2 (en) | 2011-10-05 | 2015-06-16 | Fmc Corporation | Stabilizer composition of co-attrited microcrystalline cellulose and carboxymethylcellulose, method for making, and uses |
CA2853084C (en) | 2011-10-21 | 2022-04-26 | Nova Southeastern University | Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine |
WO2013085810A2 (en) | 2011-12-09 | 2013-06-13 | Fmc Corporation | Co-attrited stabilizer composition |
US10806703B2 (en) * | 2012-01-20 | 2020-10-20 | Lts Lohmann Therapie-System Ag | Transmucosal administration system for a pharmaceutical drug |
US9763928B2 (en) | 2012-02-10 | 2017-09-19 | Niconovum Usa, Inc. | Multi-layer nicotine-containing pharmaceutical composition |
US9044035B2 (en) | 2012-04-17 | 2015-06-02 | R.J. Reynolds Tobacco Company | Remelted ingestible products |
WO2013158814A1 (en) | 2012-04-18 | 2013-10-24 | Mallinckrodt Llc | Immediate release, abuse deterrent pharmaceutical compositions |
US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
US11596599B2 (en) | 2012-05-03 | 2023-03-07 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
US9056057B2 (en) | 2012-05-03 | 2015-06-16 | Kala Pharmaceuticals, Inc. | Nanocrystals, compositions, and methods that aid particle transport in mucus |
KR102154880B1 (en) | 2012-05-03 | 2020-09-10 | 칼라 파마슈티컬스, 인크. | Pharmaceutical nanoparticles showing improved mucosal transport |
FR2994844B1 (en) * | 2012-08-31 | 2015-01-02 | Assist Publ Hopitaux De Paris | GELIFYING FORMULATION BASED ON KETAMINE |
PL2919777T3 (en) | 2012-11-13 | 2020-07-13 | Invictus Biotechnology Pty Ltd. | Transmucosal delivery of tocotrienol |
EP2935280A4 (en) | 2012-12-21 | 2016-05-25 | Map Pharmaceuticals Inc | 8'-hydroxy-dihydroergotamine compounds and compositions |
IL295091B2 (en) * | 2013-01-14 | 2023-08-01 | Infirst Healthcare Ltd | Solid solution compositions |
AU2014216178B2 (en) | 2013-02-15 | 2018-06-28 | KALA BIO, Inc. | Therapeutic compounds and uses thereof |
US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
AU2014219024B2 (en) | 2013-02-20 | 2018-04-05 | KALA BIO, Inc. | Therapeutic compounds and uses thereof |
WO2014140868A2 (en) * | 2013-03-15 | 2014-09-18 | Allen Davidoff | Xanthine oxidase inhibitor formulations |
EP2968182B8 (en) | 2013-03-15 | 2018-07-25 | SpecGx LLC | Abuse deterrent solid dosage form for immediate release with functional score |
HRP20211286T1 (en) | 2013-03-22 | 2021-12-24 | Nova Southeastern University | Epinephrine fine particles and methods for use thereof for treatment of conditions responsive to epinephrine |
US11771127B2 (en) * | 2013-10-03 | 2023-10-03 | Altria Client Services Llc | Chewable dissolvable nicotine tablet |
US11779045B2 (en) * | 2013-10-03 | 2023-10-10 | Altria Client Services Llc | Dissolvable-chewable exhausted-tobacco tablet |
MX355330B (en) | 2013-11-01 | 2018-04-16 | Kala Pharmaceuticals Inc | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS and USES THEREOF. |
US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
EP3524247A1 (en) | 2013-11-11 | 2019-08-14 | Impax Laboratories, Inc. | Rapidly disintegrating formulations and methods of use |
WO2015091485A1 (en) | 2013-12-17 | 2015-06-25 | Eos Gmbh Electro Optical Systems | Laser printing system |
PL3164117T3 (en) | 2014-07-03 | 2024-03-11 | SpecGx LLC | Abuse deterrent immediate release formulations comprising non-cellulose polysaccharides |
MY187877A (en) | 2014-12-23 | 2021-10-26 | Acelrx Pharmaceuticals Inc | Systems, devices and methods for dispensing oral transmucosal dosage forms |
US9925138B2 (en) | 2015-01-20 | 2018-03-27 | Handa Pharmaceuticals, Llc | Stable solid fingolimod dosage forms |
US9750785B2 (en) | 2015-01-30 | 2017-09-05 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9375478B1 (en) | 2015-01-30 | 2016-06-28 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9744209B2 (en) | 2015-01-30 | 2017-08-29 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9937223B2 (en) | 2015-01-30 | 2018-04-10 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9687526B2 (en) | 2015-01-30 | 2017-06-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9925233B2 (en) | 2015-01-30 | 2018-03-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
GB201504482D0 (en) * | 2015-03-17 | 2015-04-29 | King S College London | Novel formulations |
JP7211706B2 (en) | 2015-04-21 | 2023-01-24 | サノヴィオン ファーマシュティカルズ インコーポレーテッド | Method for treating Parkinson's disease by administering apomorphine to oral mucosa |
EP3322402B1 (en) * | 2015-07-16 | 2019-05-29 | Swipp Ab | Compositions of midazolam for buccal administration in the treatment of seizures to obtain rapid onset of action |
EP3509421A4 (en) | 2016-09-08 | 2020-05-20 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
EP3509422A4 (en) | 2016-09-08 | 2020-05-20 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
AU2017324716B2 (en) | 2016-09-08 | 2020-08-13 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
WO2018127938A1 (en) * | 2017-01-04 | 2018-07-12 | Jubeln Lifesciences Pvt. Ltd. | Oral dispersible film composition |
US10744087B2 (en) | 2018-03-22 | 2020-08-18 | Incarda Therapeutics, Inc. | Method to slow ventricular rate |
US10369157B1 (en) | 2018-03-29 | 2019-08-06 | Mfkc 200, Llc | Multi-agent formulation |
MX2021002459A (en) | 2018-09-25 | 2021-04-29 | SpecGx LLC | Abuse deterrent immediate release capsule dosage forms. |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5449521A (en) * | 1988-11-28 | 1995-09-12 | Vectorpharma N.A. Inc. | Supported drugs with increased dissolution rate, and a process for their preparation |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2698822A (en) * | 1951-04-28 | 1955-01-04 | Fougera & Co Inc E | Cardiac glycoside buccal composition |
US3511914A (en) * | 1967-01-31 | 1970-05-12 | Schering Corp | Throat lozenge vehicle |
US3439089A (en) * | 1968-03-27 | 1969-04-15 | Merck & Co Inc | Medicated hard candy |
US3634584A (en) * | 1969-02-13 | 1972-01-11 | American Home Prod | Sustained action dosage form |
US4151273A (en) * | 1974-10-31 | 1979-04-24 | The Regents Of The University Of California | Increasing the absorption rate of insoluble drugs |
FI82188C (en) * | 1983-03-16 | 1991-02-11 | Boehringer Ingelheim Ltd | FRAMEWORK FOR THE FRAMEWORK OF ENTRY, PHARMACEUTICAL PROVISION FOR DISPERSION OF CLORTALIDON. |
JPS6117510A (en) * | 1984-07-03 | 1986-01-25 | Toyobo Co Ltd | Gradually releasing preparation of nifedipine to be applied to oral cavity mucosa |
US4629621A (en) * | 1984-07-23 | 1986-12-16 | Zetachron, Inc. | Erodible matrix for sustained release bioactive composition |
US4624849A (en) * | 1984-11-02 | 1986-11-25 | The Procter & Gamble Company | Antimicrobial lozenges |
US5132114A (en) | 1985-05-01 | 1992-07-21 | University Of Utah Research Foundation | Compositions and methods of manufacture of compressed powder medicaments |
SE448889B (en) * | 1985-11-06 | 1987-03-23 | Sunds Defibrator | SET FOR TREATMENT OF RECOVERY PAPERS |
US4764378A (en) * | 1986-02-10 | 1988-08-16 | Zetachron, Inc. | Buccal drug dosage form |
US5047244A (en) * | 1988-06-03 | 1991-09-10 | Watson Laboratories, Inc. | Mucoadhesive carrier for delivery of therapeutical agent |
US5073374A (en) * | 1988-11-30 | 1991-12-17 | Schering Corporation | Fast dissolving buccal tablet |
AU659645B2 (en) † | 1991-06-26 | 1995-05-25 | Inhale Therapeutic Systems | Storage of materials |
JP3773062B2 (en) * | 1993-01-29 | 2006-05-10 | 味の素株式会社 | Pharmaceutical additives |
CN1060042C (en) † | 1993-10-27 | 2001-01-03 | 法玛西雅厄普约翰美国公司 | Stabilized prostaglandin E 1 |
DE19509807A1 (en) † | 1995-03-21 | 1996-09-26 | Basf Ag | Process for the preparation of active substance preparations in the form of a solid solution of the active substance in a polymer matrix, and active substance preparations produced using this method |
IT1274034B (en) | 1994-07-26 | 1997-07-14 | Applied Pharma Res | PHARMACEUTICAL COMPOSITIONS BASED ON RUBBER TO BE CHEWED AND PROCEDURE FOR THEIR PREPARATION |
JPH08291063A (en) * | 1995-04-21 | 1996-11-05 | Maruho Kk | Readily absorbable pharmaceutical preparation and its production |
ES2287971T3 (en) * | 1997-08-11 | 2007-12-16 | Pfizer Products Inc. | SOLID PHARMACEUTICAL DISPERSIONS WITH INCREASED BIODISPONIBILITY. |
JP3460538B2 (en) * | 1997-10-08 | 2003-10-27 | 救急薬品工業株式会社 | Fast dissolving film preparation |
-
1999
- 1999-10-27 US US09/428,071 patent/US6264981B1/en not_active Expired - Lifetime
-
2000
- 2000-10-12 AU AU10797/01A patent/AU1079701A/en not_active Abandoned
- 2000-10-12 AT AT00972083T patent/ATE468845T2/en active
- 2000-10-12 MX MXPA02004235A patent/MXPA02004235A/en active IP Right Grant
- 2000-10-12 PT PT00972083T patent/PT1242013E/en unknown
- 2000-10-12 DE DE60044464T patent/DE60044464D1/en not_active Expired - Lifetime
- 2000-10-12 WO PCT/US2000/028113 patent/WO2001030288A1/en active Search and Examination
- 2000-10-12 EP EP00972083.0A patent/EP1242013B2/en not_active Expired - Lifetime
- 2000-10-12 CA CA002388610A patent/CA2388610C/en not_active Expired - Fee Related
- 2000-10-12 ES ES00972083.0T patent/ES2345870T5/en not_active Expired - Lifetime
- 2000-10-12 JP JP2001532709A patent/JP4815084B2/en not_active Expired - Fee Related
-
2003
- 2003-03-25 HK HK03102146.6A patent/HK1050313A1/en not_active IP Right Cessation
-
2008
- 2008-05-07 JP JP2008121345A patent/JP2008201805A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5449521A (en) * | 1988-11-28 | 1995-09-12 | Vectorpharma N.A. Inc. | Supported drugs with increased dissolution rate, and a process for their preparation |
Cited By (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8865202B2 (en) | 1996-11-11 | 2014-10-21 | Lts Lohmann Therapie-Systeme Ag | Water soluble film for oral administration with instant wettability |
US9468604B2 (en) | 2001-06-22 | 2016-10-18 | Bend Research, Inc. | Pharmaceutical compositions of dispersions of drug and neutral polymers |
US8900498B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for manufacturing a resulting multi-layer pharmaceutical film |
US8906277B2 (en) | 2001-10-12 | 2014-12-09 | Monosol Rx, Llc | Process for manufacturing a resulting pharmaceutical film |
US10285910B2 (en) | 2001-10-12 | 2019-05-14 | Aquestive Therapeutics, Inc. | Sublingual and buccal film compositions |
US9855221B2 (en) | 2001-10-12 | 2018-01-02 | Monosol Rx, Llc | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
US9108340B2 (en) | 2001-10-12 | 2015-08-18 | Monosol Rx, Llc | Process for manufacturing a resulting multi-layer pharmaceutical film |
US9931305B2 (en) | 2001-10-12 | 2018-04-03 | Monosol Rx, Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
US10888499B2 (en) | 2001-10-12 | 2021-01-12 | Aquestive Therapeutics, Inc. | Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom |
US11077068B2 (en) | 2001-10-12 | 2021-08-03 | Aquestive Therapeutics, Inc. | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
US8900497B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for making a film having a substantially uniform distribution of components |
US8765167B2 (en) | 2001-10-12 | 2014-07-01 | Monosol Rx, Llc | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
US11207805B2 (en) | 2001-10-12 | 2021-12-28 | Aquestive Therapeutics, Inc. | Process for manufacturing a resulting pharmaceutical film |
US8652378B1 (en) | 2001-10-12 | 2014-02-18 | Monosol Rx Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
US10357455B2 (en) | 2002-02-01 | 2019-07-23 | Bend Research, Inc. | Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials |
US9486410B2 (en) | 2002-02-01 | 2016-11-08 | Bend Research, Inc. | Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials |
US10111810B2 (en) | 2002-04-11 | 2018-10-30 | Aquestive Therapeutics, Inc. | Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom |
AU2003274030B2 (en) * | 2002-11-08 | 2008-09-04 | Lts Lohmann Therapie-Systeme Ag | Transmucosal pharmaceutical administration form |
JP2006506406A (en) * | 2002-11-08 | 2006-02-23 | エルテーエス ローマン テラピー−ジステーメ アーゲー | Transmucosal pharmaceutical dosage form |
WO2004041239A1 (en) * | 2002-11-08 | 2004-05-21 | Lts Lohmann Therapie-Systeme Ag | Transmucosal pharmaceutical administration form |
JP2006513238A (en) * | 2002-12-19 | 2006-04-20 | ファルマシア・コーポレーション | Non-hygroscopic formulations containing hygroscopic drugs |
US9629832B2 (en) | 2002-12-20 | 2017-04-25 | Niconovum Usa, Inc. | Physically and chemically stable nicotine-containing particulate material |
EP1803443B1 (en) * | 2002-12-20 | 2018-10-31 | NicoNovum AB | A nicotine-containing particulate material with a crystalline cellulose |
EP1803443A2 (en) * | 2002-12-20 | 2007-07-04 | NicoNovum AB | A method for the preparation of a nicotine-containing particulate material with a crystalline cellulose (in particular MCC) |
EP3473251A1 (en) * | 2002-12-20 | 2019-04-24 | NicoNovum AB | A nicotine-cellulose combination |
WO2004069198A3 (en) * | 2003-02-04 | 2004-10-07 | Cephalon Inc | Sugar-free oral transmucosal solid dosage forms and uses thereof |
WO2004069198A2 (en) * | 2003-02-04 | 2004-08-19 | Cephalon, Inc. | Sugar-free oral transmucosal solid dosage forms and uses thereof |
JP2006516648A (en) * | 2003-02-04 | 2006-07-06 | セフアロン・インコーポレーテツド | Sugar-free oral transmucosal solid dosage forms and their use |
US8012505B2 (en) | 2003-02-28 | 2011-09-06 | Alk-Abello A/S | Dosage form having a saccharide matrix |
JP2006519187A (en) * | 2003-02-28 | 2006-08-24 | アルカベロ アクチェセルスカプ | Dosage form with saccharide matrix |
JP4688787B2 (en) * | 2003-02-28 | 2011-05-25 | アルカベロ アクチェセルスカプ | Dosage form with saccharide matrix |
US9023393B2 (en) | 2003-08-04 | 2015-05-05 | Bend Research, Inc. | Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials |
USRE47033E1 (en) | 2003-08-04 | 2018-09-11 | Bend Research, Inc. | Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials |
AU2015221520B2 (en) * | 2003-11-19 | 2017-06-08 | Salix Pharmaceuticals, Inc. | Colonic purgative composition with soluble binding agent |
AU2012202628B2 (en) * | 2003-11-19 | 2014-05-15 | Salix Pharmaceuticals, Inc. | Colonic purgative composition with soluble binding agent |
US8507009B2 (en) | 2003-11-19 | 2013-08-13 | Salix Pharmaceuticals, Inc. | Colonic purgative composition with soluble binding agent |
EP2308476A1 (en) * | 2003-11-19 | 2011-04-13 | Inkine Pharmaceutical Company, Inc. | Colonic purgative composition with soluble binding agent |
US9320721B2 (en) | 2004-09-01 | 2016-04-26 | Tesa Labtec Gmbh | Mucoadhesive patch with opposite ratios of nonionic and anionic hydrocolloids in adhesive and backing layer |
DE102005003387A1 (en) * | 2004-09-01 | 2006-03-02 | LABTEC Gesellschaft für technologische Forschung und Entwicklung mbH | Plaster for administering active agents through body orifices, comprises adhesive and backing layers, both made of nonionic and anionic hydrocolloids in reverse ratios |
WO2007009801A3 (en) * | 2005-07-20 | 2007-06-21 | Hexal Ag | Oral, quickly disintegrating film, which cannot be spit out, for a neuroleptic drug |
US10507180B2 (en) | 2006-01-06 | 2019-12-17 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
US9289583B2 (en) | 2006-01-06 | 2016-03-22 | Acelrx Pharmaceuticals, Inc. | Methods for administering small volume oral transmucosal dosage forms using a dispensing device |
US8778393B2 (en) | 2006-01-06 | 2014-07-15 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
US8865743B2 (en) | 2006-01-06 | 2014-10-21 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
US8905964B2 (en) | 2006-01-06 | 2014-12-09 | Acelrx Pharmaceuticals, Inc. | Drug storage and dispensing devices and systems comprising the same |
US8535714B2 (en) | 2006-01-06 | 2013-09-17 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
US10342762B2 (en) | 2006-01-06 | 2019-07-09 | Acelrx Pharmaceuticals, Inc. | Small-volume oral transmucosal dosage forms |
US10245228B2 (en) | 2006-01-06 | 2019-04-02 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
US8778394B2 (en) | 2006-01-06 | 2014-07-15 | Acelrx Pharmaceuticals, Inc. | Small-volume oral transmucosal dosage forms |
US9320710B2 (en) | 2006-01-06 | 2016-04-26 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
US8226978B2 (en) | 2006-01-06 | 2012-07-24 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
US9744129B2 (en) | 2006-01-06 | 2017-08-29 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
US8202535B2 (en) | 2006-01-06 | 2012-06-19 | Acelrx Pharmaceuticals, Inc. | Small-volume oral transmucosal dosage forms |
US8865211B2 (en) | 2006-01-06 | 2014-10-21 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
WO2007085498A1 (en) * | 2006-01-24 | 2007-08-02 | Bayer Schering Pharma Aktiengesellschaft | Pharmaceutical forms in film form for use in the mouth (wafers) |
US10219999B2 (en) | 2006-03-16 | 2019-03-05 | Niconovum Usa, Inc. | Snuff composition |
US11129792B2 (en) | 2006-03-16 | 2021-09-28 | Modoral Brands Inc. | Snuff composition |
US11547660B2 (en) | 2006-03-16 | 2023-01-10 | Niconovum Usa, Inc. | Snuff composition |
AU2007250588B2 (en) * | 2006-05-16 | 2013-01-31 | Mcneil Ab | Pharmaceutical product for intraoral delivery of nicotine comprising trometamol as buffering agent |
NO342308B1 (en) * | 2006-05-16 | 2018-05-07 | Mcneil Ab | Pharmaceutical product for intraoral delivery of nicotine including trometamol as buffer |
WO2007133141A1 (en) * | 2006-05-16 | 2007-11-22 | Mcneil Ab | Coated pharmaceutical product for intraoral delivery of nicotine comprising trometamol as buffering agent |
WO2007133140A1 (en) * | 2006-05-16 | 2007-11-22 | Mcneil Ab | Pharmaceutical product for intraoral delivery of nicotine comprising trometamol as buffering agent |
WO2008011194A2 (en) * | 2006-07-21 | 2008-01-24 | Biodelivery Sciences International, Inc. | Transmucosal delivery devices with enhanced uptake |
RU2504377C2 (en) * | 2006-07-21 | 2014-01-20 | БайоДеливери Сайенсиз Интэнэшнл, Инк. | Method for transmucosal drug delivery, agent for transmucosal drug delivery (versions) and method for pain management |
US9655843B2 (en) | 2006-07-21 | 2017-05-23 | Biodelivery Sciences International, Inc. | Transmucosal delivery devices with enhanced uptake |
WO2008011177A2 (en) * | 2006-07-21 | 2008-01-24 | Jsrnti, Llc | Medicinal delivery system and related methods |
WO2008011177A3 (en) * | 2006-07-21 | 2008-03-06 | Jsrnti Llc | Medicinal delivery system and related methods |
US10799449B2 (en) | 2006-07-21 | 2020-10-13 | Jsrnti, Llc | Medicinal delivery system and related methods |
NO344719B1 (en) * | 2006-07-21 | 2020-03-23 | Biodelivery Sciences Int Inc | TRANSMUCOSAL DELIVERY DEVICE WITH INCREASED RECORDING |
WO2008011194A3 (en) * | 2006-07-21 | 2008-05-15 | Biodelivery Sciences Int Inc | Transmucosal delivery devices with enhanced uptake |
EP3566692A1 (en) * | 2006-07-21 | 2019-11-13 | BioDelivery Sciences International, Inc. | Transmucosal delivery devices with enhanced uptake |
US9597288B2 (en) | 2006-07-21 | 2017-03-21 | Biodelivery Sciences International, Inc. | Transmucosal delivery devices with enhanced uptake |
EP3067044A1 (en) * | 2006-07-21 | 2016-09-14 | BioDelivery Sciences International, Inc. | Transmucosal delivery devices with enhanced uptake |
AU2007275581B2 (en) * | 2006-07-21 | 2011-09-08 | Biodelivery Sciences International, Inc. | Transmucosal delivery devices with enhanced uptake |
AU2007275565B2 (en) * | 2006-07-21 | 2012-07-19 | Jsrnti, Llc | Medicinal delivery system and related methods |
WO2008085765A3 (en) * | 2007-01-05 | 2008-11-27 | Acelrx Pharmaceuticals Inc | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
KR101545754B1 (en) | 2007-01-05 | 2015-08-19 | 아셀알엑스 파마슈티컬스 인코퍼레이티드 | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
CN101621994B (en) * | 2007-01-05 | 2016-06-01 | 阿塞尔Rx制药有限公司 | For treating a small amount of oral transmucosal dosage forms containing sufentanil of pain |
US9066847B2 (en) | 2007-01-05 | 2015-06-30 | Aceirx Pharmaceuticals, Inc. | Storage and dispensing devices for administration of oral transmucosal dosage forms |
US8945592B2 (en) | 2008-11-21 | 2015-02-03 | Acelrx Pharmaceuticals, Inc. | Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same |
US10821074B2 (en) | 2009-08-07 | 2020-11-03 | Aquestive Therapeutics, Inc. | Sublingual and buccal film compositions |
WO2011047143A1 (en) * | 2009-10-16 | 2011-04-21 | Acelrx Pharmaceuticals, Inc. | Compositions and methods for mild sedation, anxiolysis and analgesia in the procedural setting |
US10272607B2 (en) | 2010-10-22 | 2019-04-30 | Aquestive Therapeutics, Inc. | Manufacturing of small film strips |
US10940626B2 (en) | 2010-10-22 | 2021-03-09 | Aquestive Therapeutics, Inc. | Manufacturing of small film strips |
EP3939569A1 (en) | 2011-09-19 | 2022-01-19 | Orexo AB | New abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
US9259421B2 (en) | 2011-09-19 | 2016-02-16 | Orexo Ab | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
US9439900B2 (en) | 2011-09-19 | 2016-09-13 | Orexo Ab | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
US10874661B2 (en) | 2011-09-19 | 2020-12-29 | Orexo Ab | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
EP2915525A1 (en) | 2011-09-19 | 2015-09-09 | Orexo AB | Sublingual abuse-resistant tablets comprising buprenorphine and naloxone |
US8940330B2 (en) | 2011-09-19 | 2015-01-27 | Orexo Ab | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
US10946010B2 (en) | 2011-09-19 | 2021-03-16 | Orexo Ab | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
US11020388B2 (en) | 2011-09-19 | 2021-06-01 | Orexo Ab | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
US11020387B2 (en) | 2011-09-19 | 2021-06-01 | Orexo Ab | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
US11433066B2 (en) | 2011-09-19 | 2022-09-06 | Orexo Ab | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
WO2013041851A1 (en) | 2011-09-19 | 2013-03-28 | Orexo Ab | New abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
US9901539B2 (en) | 2011-12-21 | 2018-02-27 | Biodelivery Sciences International, Inc. | Transmucosal drug delivery devices for use in chronic pain relief |
US8815911B2 (en) | 2012-05-02 | 2014-08-26 | Orexo Ab | Alfentanil composition for the treatment of acute pain |
US9345698B2 (en) | 2012-05-02 | 2016-05-24 | Orexo Ab | Alfentanil composition for the treatment of acute pain |
US9782396B2 (en) | 2012-05-02 | 2017-10-10 | Orexo Ab | Alfentanil composition for the treatment of acute pain |
US11191737B2 (en) | 2016-05-05 | 2021-12-07 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine compositions |
US11273131B2 (en) | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
US11737980B2 (en) | 2020-05-18 | 2023-08-29 | Orexo Ab | Pharmaceutical composition for drug delivery |
US11957647B2 (en) | 2021-11-25 | 2024-04-16 | Orexo Ab | Pharmaceutical composition comprising adrenaline |
WO2023187664A1 (en) * | 2022-03-30 | 2023-10-05 | Avaca Pharma Private Limited | A pharmaceutical composition for the treatment of immune system mediated diseases |
Also Published As
Publication number | Publication date |
---|---|
HK1050313A1 (en) | 2003-06-20 |
EP1242013B2 (en) | 2017-12-06 |
MXPA02004235A (en) | 2004-04-21 |
DE60044464D1 (en) | 2010-07-08 |
JP2008201805A (en) | 2008-09-04 |
ATE468845T2 (en) | 2010-06-15 |
US6264981B1 (en) | 2001-07-24 |
ES2345870T3 (en) | 2010-10-05 |
CA2388610C (en) | 2007-08-21 |
PT1242013E (en) | 2010-07-14 |
EP1242013A4 (en) | 2005-06-15 |
EP1242013A1 (en) | 2002-09-25 |
JP2003512402A (en) | 2003-04-02 |
CA2388610A1 (en) | 2001-05-03 |
ES2345870T5 (en) | 2018-02-12 |
AU1079701A (en) | 2001-05-08 |
JP4815084B2 (en) | 2011-11-16 |
EP1242013B1 (en) | 2010-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6264981B1 (en) | Oral transmucosal drug dosage using solid solution | |
US8992974B2 (en) | Transmucosal drug delivery system | |
US10172810B2 (en) | Transmucosal ketamine delivery composition | |
US9358296B2 (en) | Transmucosal drug delivery system | |
US9549897B2 (en) | Transmucosal hormone delivery system | |
US11213484B2 (en) | Dipivefrin orally disintegrating tablet formulations | |
US20190365641A1 (en) | Rapidly disintegrating formulations and methods of use | |
US20050065175A1 (en) | Oral transmucosal methadone | |
US20170056320A1 (en) | Transmucosal drug delivery system | |
US20140303227A1 (en) | Transmucosal hormone delivery system | |
US20150080442A1 (en) | Transmucosal drug delivery system | |
KR20020014570A (en) | Process for Preparing Amorphous-type Ipriflavone by Solid-Dispersion | |
US20140256765A1 (en) | Transmucosal drug delivery system | |
US20140256822A1 (en) | Transmucosal drug delivery system | |
WO2020121027A1 (en) | Amorphous alprazolam compositions with anxiolytic activity with ethyl cellulose and crospovidone and corresponding methods | |
US20140303128A1 (en) | Transmucosal hormone delivery system | |
AU2004216098B2 (en) | Transmucosal drug delivery system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2388610 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 532709 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/004235 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000972083 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000972083 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) |